Our Mission
To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
The U.S. Weight Loss Market: Status Report & 2026 Forecast
March 2026 108 Pages 27 tables/charts Price: $995
This new Marketdata report presents a wrap-up of 2025 performance for the U.S. weight loss market during the obesity drugs market explosion and a forecast for 2026. The value of the total market is estimated to have grown to a historic peak of $135 billion in 2025, boosted by soaring sales of the popular prescription GLP-1 weight loss drugs. This is a paradigm shift to medical programs, and a major challenge for competing commercial diet companies.
GLP-1 drugs are a game changer in terms of the number of medications now on the market, plus others to come in the next several years. They have affected dieter behavior and how commercial diet companies operate. Nearly all non-medical segments of the market have felt the pain of declining sales, and 26,000+ weight loss coaches have lost their jobs. However, more physicians are adding weight loss to their practices, the number of bariatricians are hitting new highs, and the number of medical weight loss centers has grown.
The report includes in-depth analyses of: 2024-2025 market/revenue performance, recent competitor and market developments, current dieter trends and top diet plans, and diet company advertising and marketing spending. Special emphasis and analysis of the obesity drugs market and its effect on all market segments. Coverage of cheaper compounded drugs that are not FDA-approved, new drugs entering the market.
Individual Status Reports and the effects of the obesity drugs boom on operations and revenues, for ALL major weight loss market segments… diet soft drinks, artificial sweeteners, health clubs industry, commercial weight loss chains, retail meal replacements and appetite suppressants, and low-calorie dinner entrees.
Medical programs covered in depth (MD programs, hospitals/clinic programs, prescription diet drugs, bariatricians, weight loss surgeries, very low calorie diet vendors).
Icludes profiles/updated outlooks/strategies/revenues for: Weight Watchers, NutriSystem, Jenny Craig, Medifast, Herbalife, Glanbia (Slim-Fast), Noom, Simply Good Foods (Dr. Atkins product line), HMR, Lindora, Beach Body, AMWAY, Bellring Brands (Premier Protein), Novo Nordisk, Eli Lilly.
Latest News
New Eli Lilly Weight Loss Pill Approved – Foundayo
April 2, 2026 On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and, unlike some other GLP-1s, does not need to be taken on an empty stomach. Foundayo is the second oral GLP-1 weight loss pill approved, following
Weight Watchers Reports Q4 & Full Year 2025 Results, 2026 Guidance
March 17, 2026 Weight Watchers reports its 2025 results yesterday. The firm’s revenues came in at $710 million, a 9.6% decline from 2024 revenues of $786 million. The company is expecting an 11% decrease in 2026 revenues, to between $620 and $635 million. 2025 Total Revenue and Adjusted EBITDA above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first
A Tale of Two MLM Competitors
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an estimated 0.7% in 2025, to an estimated $563 million. Why the big difference? The two companies are selling very similar weight loss products, using the
FDA Cracks Down on Telehealth Companies
March 12, 2026 The FDA is finally cracking down on telehealth companies marketing compounded weight loss drugs, warning them not to imply their products are FDA-approved or that they manufacture the medications. Roughly 30% of the more than 70 telehealth companies warned in the past six months rely on just four nationwide “white-label” medical groups — Beluga Health, OpenLoop, MD Integrations, and Telegra — that provide the clinicians who actually prescribe the drugs. The telehealth companies that have been warned
Marketdata weight loss reports have been quoted by..
